Cargando…

Time–Action Profile of Technosphere Insulin in Children with Type 1 Diabetes

INTRODUCTION: Technosphere insulin (TI) is an inhaled dry powder ultra-rapid-acting insulin. This report describes the results of the first study of TI in children with type 1 diabetes (T1D). METHODS: Pharmacokinetics (PK) of TI and the effect of TI on circulating glucose concentrations were evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haller, Michael J., Jones, Marisa C., Bhavsar, Sunil, Kaiserman, Kevin B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981820/ https://www.ncbi.nlm.nih.gov/pubmed/36652106 http://dx.doi.org/10.1007/s13300-023-01368-7

Ejemplares similares

Place of technosphere inhaled insulin in treatment of diabetes
por: Mikhail, Nasser
Publicado: (2016)

Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled With Oral Agents
por: Rosenstock, Julio, et al.
Publicado: (2008)

Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere inhaled insulin
por: Levin, Philip A, et al.
Publicado: (2016)

Hypoglycaemia is reduced with use of inhaled Technosphere(®) Insulin relative to insulin aspart in type 1 diabetes mellitus
por: Seaquist, E. R., et al.
Publicado: (2019)

Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus
por: Grant, Marshall, et al.
Publicado: (2021)

Comprehensive Pulmonary Safety Review of Inhaled Technosphere(®) Insulin in Patients with Diabetes Mellitus
por: McGill, Janet B., et al.
Publicado: (2020)

Case Report: Efficient Avoidance of Hospitalization for Diabetic Ketosis Utilizing Technosphere Inhaled Insulin
por: Bell, David S. H., et al.
Publicado: (2020)

Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study
por: Akturk, Halis Kaan, et al.
Publicado: (2018)

A Population Dose–Response Model for Inhaled Technosphere Insulin Administered to Healthy Subjects
por: Rüppel, D, et al.
Publicado: (2017)

Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator
por: Visentin, Roberto, et al.
Publicado: (2016)

Geek and hacker stories: code, culture and storytelling from the technosphere
por: Alleyne, Brian
Publicado: (2018)

Planetary Scale Information Transmission in the Biosphere and Technosphere: Limits and Evolution
por: Lingam, Manasvi, et al.
Publicado: (2023)

Initiating insulin therapy in children and adolescents with type 1 diabetes mellitus
por: Wangnoo, Subhash Kumar
Publicado: (2015)

Faster insulin action is associated with improved glycaemic outcomes during closed‐loop insulin delivery and sensor‐augmented pump therapy in adults with type 1 diabetes
por: Ruan, Yue, et al.
Publicado: (2017)

Glycaemic profiles of diverse patients with type 2 diabetes using basal insulin: MOBILE study baseline data
por: Peters, Anne, et al.
Publicado: (2020)

BDNF Action in the Brain Attenuates Diabetic Hyperglycemia via Insulin-Independent Inhibition of Hepatic Glucose Production
por: Meek, Thomas H., et al.
Publicado: (2013)

Technospheric Mining of Rare Earth Elements from Bauxite Residue (Red Mud): Process Optimization, Kinetic Investigation, and Microwave Pretreatment
por: Reid, Sable, et al.
Publicado: (2017)

Glucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: An observational study
por: Kietsiriroje, Noppadol, et al.
Publicado: (2022)

Choice of Insulin in Type 2 Diabetes: A Southeast Asian Perspective
por: Kalra, Sanjay, et al.
Publicado: (2017)

Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus
por: Bruinstroop, Eveline, et al.
Publicado: (2018)

Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen
por: Onishi, Yukiko, et al.
Publicado: (2020)

Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100
por: Alexopoulos, Anastasia‐Stefania, et al.
Publicado: (2021)

Insulin action in adipose tissue in type 1 diabetes
por: Arrieta-Blanco, Francisco, et al.
Publicado: (2011)

Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program
por: Khunti, Kamlesh, et al.
Publicado: (2017)

Time-action profiles of insulin degludec in healthy dogs and its effects on glycemic control in diabetic dogs
por: ODA, Hitomi, et al.
Publicado: (2018)

Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study
por: Goldenberg, Ronald M., et al.
Publicado: (2023)

Glucose-regulated insulin production in the liver improves glycemic control in type 1 diabetic mice()
por: Zhang, Ting, et al.
Publicado: (2014)

Correlations between anthropometry and lipid profile in type 2 diabetics
por: Himabindu, Yalamanchali, et al.
Publicado: (2013)

Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
por: Vilsbøll, Tina, et al.
Publicado: (2019)

Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying
por: Marathe, Chinmay S., et al.
Publicado: (2022)

Using an Advanced Practice Pharmacist in a Team-Based Care Model to Decrease Time to Hemoglobin A(1c) Goal Among Patients With Type 2 Diabetes, Florida, 2017–2019
por: Cowart, Kevin, et al.
Publicado: (2020)

Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey
por: Svensson, Ann-Marie, et al.
Publicado: (2020)

Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin
por: Zhou, Fang Liz, et al.
Publicado: (2018)

Moving Time: The Influence of Action on Duration Perception
por: Press, Clare, et al.
Publicado: (2014)

Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
por: Blonde, Lawrence, et al.
Publicado: (2018)

Route of Insulin Does Not Influence 25-Hydroxyvitamin D Concentrations in Type 1 Diabetes: A Brief Report
por: van Dijk, Peter R, et al.
Publicado: (2019)

IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy
por: Watada, Hirotaka, et al.
Publicado: (2019)

Evaluation of severe hypoglycemia and common mental disorders in patients receiving insulin analogues for treatment of type 1 diabetes
por: Berlanda, Gabriela, et al.
Publicado: (2020)

Type 2 diabetes in children: Clinical aspects and risk factors
por: Rao, P. V.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jflabcrlnddjrkum9gho8mddib